Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study Fibrocytes in patients with Rheumatoid Arthritis, Interstitial lung disease and severe asthma and healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunopathologic Profiles and Blood Biomarkers in Patients With IPF

NCT04187079

Idiopathic Pulmonary Fibrosis

COMPLETED

The Role of Endothelium A and EGFR Receptor in Fibrocytes From Asthma With Obstructive Sleep Apnea

NCT02749565

Asthma OSA

UNKNOWN

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327

Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis +1 more

RECRUITING

Prediction of Pulmonary Problems

NCT07047391

Respiratory Muscle Strength Oxygen Saturation Rheumatoid Arthritis (RA)

COMPLETED

Cryoprobe Transbronchial Lung Biospy in Patients With Mechanical Ventilation

NCT02611297

Lung Diseases Interstitial Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives: 1) To demonstrate that circulating CD45+ CD34+ CD11b+ cells can express Procollagen 1 and thereby show that these markers can be used to identify circulating fibrocytes. 2) To measure the levels of circulating CD45+, CD34+, CD11b+ cells in patients with RA, Fibrotic ILDs, severe asthma and in healthy controls (HC). 3) To compare the levels with number of peripheral blood mononuclear cells (PBMC) that differentiate to mature fibrocytes in vitro.

Method: The CD45+, CD34+, CD11b+ cells from 4 patients were isolated by cell sorting, and stained for Procollagen. 30 patients (10 of each RA, fibrotic ILDs: IPF or non-specific interstitial pneumonitis (NSIP), severe asthma) and 10 HC were included. Current medication, disease activity, lung function and radiographic data were collected. In 100 µL of lysed blood cells were enumerated by flowcytometry. Further, PBMC were isolated and cultured for 5 days. Coverslips from two wells were stained and mature fibrocytes counted and reported as fibrocytes per 106 PBMC originally added to the well.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Diseases Rheumatoid Arthritis Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fibrocyte measurement and lung function test

All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.

Group Type EXPERIMENTAL

Fibrocyte measurement and lung function test.

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fibrocyte measurement and lung function test.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 10 patient with rheumatoid arthritis.
* 10 patient with rheumatoid arthritis and interstitial lung disease
* 10 patients with interstitial lung disease (idiopathic pulmonary fibrosis or nonspecific interstitial pneumonia)
* 10 patients with asthma
* 10 healthy volunteers